NY-LIME-TRADNG/TKEPROFIT
2.5.2024 14:01:30 CEST | Business Wire | Press release
Lime Trading Corp (“Lime Trading”), a tech-first agency broker headquartered in New York City, proudly announces its strategic partnership with west coast start up TakeProfit, a pioneering community-driven trader platform based in San Francisco, California. This collaboration was born from a joint belief that traders should have access to the best tools and technology no matter their strategy. This new partnership offers retail traders access to the newest innovations in charting and technical analysis, coupled with Lime Trading's industry-leading trade execution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502144682/en/
The newly launched TakeProfit trading platform now offers widgets that integrate seamlessly with Lime Trading. Lime clients will be able to now place trades from the TakeProfit platform and view their portfolio all in one place. (Graphic: Business Wire)
Lime Trading is the only broker connected to TakeProfit, offering exclusive access to a trading widget native to the TakeProfit platform. Now traders can ideate and trade in one, seamless experience without ever leaving the platform. “We are thrilled to introduce this integration with TakeProfit,” remarked Johan Sandblom, CEO at Lime Trading. “By merging Lime Trading's expertise in trade execution with TakeProfit's innovative platform, we are equipping retail traders with the essential tools needed to help navigate today's dynamic markets efficiently.”
Alexey Shulzhenko, TakeProfit’s Founder & CEO said, “We partnered with Lime because they have a passion to build the best for traders, by traders. Their focus on providing all traders with lower latency technology aligns with our mission to bring traders the tools they need to trade more effectively.”
This partnership is just one of a few, recent product enhancements that Lime Trading has released to enhance their retail offering. Most recently they’ve added a Python SDK for their REST API and streamlined their demo paper trading access for traders to test drive Lime for themselves.
Traders wanting to try the TakeProfit trade integration that do not yet have a Lime account to experience this new integration, are able to sign up for a free demo paper account. For more information regarding Lime Trading and TakeProfit's new partnership, visit m.lime.co/takeprofit.
About Lime Trading
For over twenty years, Lime Trading has been focused on developing tools and technology to enhance traders’ access to markets. Focused on lower latency execution, Lime Trading works with retail and institutional clients alike to offer a broad range of APIs, platforms, and technology solutions to traders worldwide. Lime Trading Corp is an SEC-registered broker-dealer, member of FINRA/SIPC/NFA. For more information, visit Lime.co.
About TakeProfit
TakeProfit is a community-driven trading platform equipped with monetization tools for traders. It facilitates sharing research and making better trading decisions, allowing members to capitalize on their expertise. Workspaces are created using widgets, providing a customizable trading environment with immersive charting, custom indicators, screeners, financials, and other tools. TakeProfit brings desktop functionality to the web, utilizing new browser technologies and leveraging the advantages of cloud products. Learn more about TakeProfit at TakeProfit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502144682/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom